Amphastar P (AMPH)
Amphastar Pharmaceuticals, Inc. is a biopharmaceutical company focused on generic and proprietary injectable, inhalation, and intranasal medicines. Through its common stock listed on NASDAQ under the symbol AMPH, the company serves markets in the United States, China, and France. Its product portfolio includes treatments used in emergency care, respiratory conditions, diabetes-related hypoglycemia, opioid overdose, anticoagulation, and other hospital and procedural settings. Amphastar also supplies active pharmaceutical ingredient products, including recombinant human insulin and porcine insulin API. Founded in 1996 and based in Rancho Cucamonga, California, the company operates within the healthcare sector and pharmaceuticals industry.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-AMPH
|
$29.46
|
48.6% Upside
|
Undervalued
|
$22
|
10.9% Upside
|
Fair
|
Great
|
—
|
—
|
—
|
0.0%
|
August 10, 2026
|
11.0x
|
1.1x
|
1.2x
|
865.5 M
|
1.265 B
|
44.2%
|
74.5%
|
3.1
|
—
|
170.6%
|
